IP Library Granted Patent US 8,153,656
Granted Patent B2
US 8,153,656 · App. 12/180,259 · Granted Apr 10, 2012

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,656
App. No.
12/180,259
Granted
Apr 10, 2012
Kind
B2
Abstract

Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

Claims (199)

1. A compound of formula (I):

or any optical isomer, diastereomer, enantiomer, tautomer, or physiologically acceptable salt thereof;

wherein R 1 and R 2 are, independently, hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl or C 1 -C 4 carboxyl; or R 1 and R 2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R 1 and R 3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms;

wherein one of R 3 and R 4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, and the other of R 3 and R 4 is hydrogen or C 1 -C 4 alkyl, the stereocenters being either ‘R’ or ‘S’ in configuration independently; and

wherein X 1 and X 2 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl or C 1 -C 4 carboxyl.

2. The compound according to claim 1 , wherein one of R 3 and R 4 is C 1 -C 8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

3. The compound according to claim 2 , wherein R 1 and R 2 are, independently, hydrogen or methyl.

4. The compound according to claim 1 , wherein X 1 and X 2 are, independently, hydrogen, hydroxy, chloro or fluoro.

5. The compound according to claim 1 , wherein one of R 3 and R 4 is C 1 -C 8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R 1 and R 2 are, independently, hydrogen or methyl; and wherein X 1 and X 2 are, independently, hydrogen, hydroxyl, chloro or fluoro.

6. The compound according to claim 5 , wherein the other of R 3 and R 4 is hydrogen.

7. The compound according to claim 1 , wherein one of R 3 and R 4 is aryl or heteroaryl.

8. The compound according to claim 7 , wherein one of R 3 and R 4 is thienyl.

9. The compound according to claim 7 , wherein one of R 3 and R 4 is monosubstituted phenyl or monosubstituted thienyl.

10. The compound according to claim 9 , wherein the substituent is fluoro, chloro or cyano.

11. The compound according to claim 7 , wherein one of R 3 and R 4 is unsubstituted phenyl or unsubstituted thienyl.

12. The compound according to claim 1 , wherein X 1 is hydroxy and X 2 is hydrogen.

13. The compound according to claim 1 , wherein a hydroxy is at the 1-position.

14. The compound according to claim 1 , wherein a hydrogen is at the 1-position.

15. The compound according to claim 1 having a formula of:

X

R 3

R 2

R 1

H

(S)—C 6 H 5

H

H

H

(R)—C 6 H 5

H

H

OH

(S)—C 6 H 5

H

H

OH

(R)—C 6 H 5

H

H

OH

(S)—C 6 H 5

Me

Me

H

(±)-o-chloro-C 6 H 4

H

H

OH

(±)-o-chloro-C 6 H 4

H

H

H

(±)-p-fluoro-C 6 H 4

H

H

OH

(±)-p-fluoro-C 6 H 4

H

H

H

(S)-3-thienyl

H

H

OH

(S)-3-thienyl

H

H

H

(S)-3-thienyl

Me

Me

OH

(S)-3-thienyl

Me

Me

H

(S)-2-thienyl

Me

Me

or the formula:

X

R 4

R 2

R 1

OH

(±)-3-thienyl

Me

Me

H

C 6 H 5

H

H

H

C 6 H 5

Me

Me

OH

C 6 H 5

H

H

or the formula:

X

R 1

R 2

R 3

H

(S)—C 6 H 5

Me

Me

H

(R)-3-thienyl

H

H

OH

(R)-3-thienyl

H

H

H

(S)-2-thienyl

H

H

OH

(S)-2-thienyl

H

H

OH

(S)-2-thienyl

Me

Me

H

(R)—CH 2 -3-thienyl

H

H

H

(S)—CH 2 -2-thienyl

H

H

H

(S)-2-furyl

H

H

H

(S)-3-pyridyl

H

H

H

(S)-2-methoxy-5-

H

H

pyridyl

or the formula:

X

R 1

R 2

R 3

H

(±)-3-thienyl

H

H

H

(±)-3-thienyl

Me

Me

H

C 6 H 5

Me

H

H

4-fluoro-C 6 H 4

H

H

16. The compound according to claim 1 , wherein R 1 and R 2 are, independently, hydrogen or methyl; R 3 is hydrogen, R 4 is phenyl; X 1 and X 2 are hydrogen.

17. A compound of formula (II):

or any optical isomer, diastereomer, enantiomer, tautomer, or physiologically acceptable salt thereof;

wherein R 1 and R 2 are, independently, hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl or C 1 -C 4 carboxyl; or R 1 and R 2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R 1 and R 3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms;

wherein one of R 3 , R 4 and R 5 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, and the other two of R 3 , R 4 and R 5 are, independently, hydrogen or C 1 -C 4 alkyl, the stereocenters being either ‘R’ or ‘S’ in configuration independently; and

wherein, X 1 and X 2 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl or C 1 -C 4 carboxyl.

18. The compound according to claim 17 , wherein one of R 3 , R 4 and R 5 is C r C 5 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

19. The compound according to claim 18 , wherein R 1 and R 2 are, independently, hydrogen or methyl.

20. The compound according to claim 17 , wherein X 1 and X 2 are, independently, hydrogen, hydroxy, chloro or fluoro.

21. The compound according to claim 17 , wherein one of R 3 , R 4 and R 5 is C 1 -C 8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R 1 and R 2 are, independently, hydrogen or methyl; and wherein X 1 and X 2 are, independently, hydrogen, hydroxyl, chloro or fluoro.

22. The compound according to claim 21 , wherein the other of R 3 , R 4 and R 5 are hydrogen.

23. The compound according to claim 17 , wherein one of R 3 , R 4 and R 5 is aryl or heteroaryl.

24. The compound according to claim 23 , wherein one of R 3 , R 4 and R 5 is thienyl.

25. The compound according to claim 23 , wherein one of R 3 , R 4 and R 5 is monosubstituted phenyl or monosubstituted thienyl.

26. The compound according to claim 25 , wherein the substituent is fluoro, chloro or cyano.

27. The compound according to claim 23 , wherein one of R 3 , R 4 and R 5 is unsubstituted phenyl or unsubstituted thienyl.

28. The compound according to claim 17 , wherein X 1 is hydroxy and X 2 is hydrogen.

29. The compound according to claim 17 , wherein a hydroxy is at the 1-position.

30. The compound according to claim 17 , wherein a hydrogen is at the 1-position.

31. The compound according to claim 17 , wherein R 1 and R 2 are, independently, hydrogen or methyl; R 3 and R 4 are hydrogen, R 5 is phenyl; X 1 and X 2 are hydrogen.

32. A composition comprising a compound according to claim 1 and a carrier.

33. The composition of claim 32 , wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.

34. A composition comprising a compound according to claim 17 and a carrier.

35. The composition of claim 34 , wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.

36. A method of treating a disease in a subject comprising:

administering to a subject an effective amount of a compound according to claim 1 ;

wherein the disease comprises eye disease.

37. The method of claim 36 , wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
RELEASE OF SECURITY INTEREST Recorded Sep 5, 2019
From: DEERFIELD PRIVATE DESIGN FUND III, L.P.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 050276/0807 →
SECURITY INTEREST Recorded Jul 23, 2018
From: AERIE PHARMACEUTICALS, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 046432/0307 →
RELEASE OF SECURITY INTEREST Recorded Jul 23, 2018
From: DEERFIELD PARTNERS, L.P.; DEERFIELD PRIVATE DESIGN FUND III, L.P.; DEERFIELD SPECIAL SITUATIONS FUND, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.
To: AERIE DISTRIBUTION, INC.
Reel/Frame 046431/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: AERIE DISTRIBUTION, INC.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 041754/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: AERIE PHARMACEUTICALS, INC.
To: AERIE DISTRIBUTION, INC.
Reel/Frame 041754/0369 →
SECURITY AGREEMENT Recorded Mar 4, 2009
From: AERIE PHARMACEUTICALS, INC.
To: ACP IV, LP, (AS COLLATERAL AGENT)
Reel/Frame 022368/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: DELONG, MITCHELL A.; STURDIVANT, JILL MARIE; ROYALTY, SUSAN M.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 022076/0456 →